Antibody targeting osteoclast-related protein Siglec-15
US9090692B2 · kind B2 · utility
2Cited by
9References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 27, 2012 |
| Grant date | Jul 28, 2015 |
| Priority date | — |
| Expiry date | Jun 25, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.